Streetbeat News

Stock Prices

GS

Goldman Sachs CEO David Solomon hinted at Bitcoin's potential as a 'store of value' during an interview, while the bank continues to invest in digital assets and plans to initiate tokenization projects by 2024.

Portfolio Pulse from Khyathi Dalal

July 30, 2024 | 7:18 pm

PSTG

Investors have taken a bearish stance on Pure Storage (NYSE:PSTG) with significant options activity indicating a potential decline. Benzinga's options scanner detected 19 trades, predominantly puts, suggesting a negative outlook. The stock is currently down 3.83% at $55.97, with analysts setting a price target of $47.0.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 7:16 pm

SNOW

The options market shows a bearish sentiment towards Snowflake (NYSE:SNOW), with 62% of recent trades being bearish. Significant investors are targeting a price range of $80 to $200. The stock is currently trading at $128.3, down by 0.98%, and may be approaching oversold territory. Analysts have mixed ratings with a consensus target price of $198.33.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 7:16 pm

AMD

AMKR

LSCC

NVDA

NVIDIA shares are trading lower amid a broader market pullback as investors brace for big tech earnings reports. AMD's upcoming earnings report is expected to provide insights into the chip market. Amkor Technology and Lattice Semiconductor shares are also down, with Lattice reporting worse-than-expected results.

Portfolio Pulse from Vaishali Prayag

July 30, 2024 | 7:12 pm

SFM

Sprouts Farmers Market, Inc. (NASDAQ:SFM) shares surged following strong Q2 2024 results and upbeat Q3 guidance. The company reported adjusted EPS of 91 cents, beating estimates of 78 cents, and sales of $1.890 billion, surpassing the forecasted $1.835 billion. Analysts have upgraded their ratings and raised price targets for SFM, contributing to a 14.5% increase in share price to $96.93.

Portfolio Pulse from Vaishali Prayag

July 30, 2024 | 7:11 pm

NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) released positive topline data from its Phase 3 BROOKLYN trial for obicetrapib, showing significant LDL-C reduction in HeFH patients. Despite meeting primary endpoints, the stock experienced volatility, closing 8.35% lower. Analyst William Blair remains confident in the drug's potential, reiterating an Outperform rating.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 7:10 pm

AIPI

PLTR

SHLD

Palantir Technologies Inc. (NYSE:PLTR) shares are trading lower by 2.99% to $26.27. Despite a 32% gain over the past year, Citigroup analyst Tyler Radke maintains a Neutral rating but raises the price target to $28. Palantir is expected to report Q2 earnings of 8 cents per share and revenue of $652.141 million on Aug. 5. The company recently announced a multi-year partnership with Tree Energy Solutions and has achieved six consecutive quarters of GAAP profitability. Wedbush analyst Dan Ives set a new bull-case price target of $50.

Portfolio Pulse from Nabaparna Bhattacharya

July 30, 2024 | 7:07 pm

UNIUSD

Uniswap (UNI) has experienced a 4.79% price drop in the past 24 hours, continuing a week-long decline of 4.0%. Trading volume has decreased by 37.0% over the past week, while circulating supply has slightly increased. The current market cap is $5.58 billion, ranking UNI at #20.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 7:02 pm

NVO

The FDA has issued a warning about the risks of overdoses and adverse events related to compounded semaglutide injectable products, such as Wegovy and Ozempic, which are not FDA-approved. These errors often result from incorrect dosing by patients and healthcare providers. Novo Nordisk's FDA-approved semaglutide products, including Wegovy, Ozempic, and Rybelsus, are designed to mitigate these risks.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 7:02 pm

PEPEUSD

Pepe (CRYPTO: PEPE) has seen a price decrease of 4.98% in the past 24 hours, continuing a week-long downward trend of 7.0%. Trading volume has dropped by 49.0% over the past week, while the circulating supply has increased by 0.48%. The current market cap ranking for PEPE is #25 at $4.75 billion.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 7:02 pm